Literature DB >> 34387201

Effects of Subnormothermic Regulated Hepatic Reperfusion on Mitochondrial and Transcriptomic Profiles in a Porcine Model.

Joohyun Kim1, Michael A Zimmerman, Woo Young Shin, Brent T Boettcher, Ju-Seog Lee, Jong-In Park, Muhammed Ali, Meiying Yang, Jyotsna Mishra, Catherine E Hagen, Joseph E McGraw, Angela Mathison, Harvey J Woehlck, Gwen Lomberk, Amadou K S Camara, Raul A Urrutia, David F Stowe, Johnny C Hong.   

Abstract

OBJECTIVE: We sought to investigate the biological effects of pre-reperfusion treatments of the liver after warm and cold ischemic injuries in a porcine donation after circulatory death (DCD) model. SUMMARY OF BACKGROUND DATA: DCD represents a severe form of liver ischemia and reperfusion injury that has a profound impact on graft function after liver transplantation.
METHODS: Twenty donor pig livers underwent 60 minutes of in situ warm ischemia after circulatory arrest and 120 minutes of cold static preservation prior to simulated transplantation using an ex vivo perfusion machine. Four reperfusion treatments were compared: Control-Normothermic (N), Control-Subnormothermic (S), regulated hepatic reperfusion (RHR)-N, and RHR-S (n = 5 each). The biochemical, metabolic, and transcriptomic profiles, as well as mitochondrial function were analyzed.
RESULTS: Compared to the other groups, RHR-S treated group showed significantly lower post-reperfusion aspartate aminotransferase levels in the reperfusion effluent and histologic findings of hepatocyte viability and lesser degree of congestion and necrosis. RHR-S resulted in a significantly higher mitochondrial respiratory control index and calcium retention capacity. Transcriptomic profile analysis showed that treatment with RHR-S activated cell survival and viability, cellular homeostasis as well as other biological functions involved in tissue repair such as cytoskeleton or cytoplasm organization, cell migration, transcription, and microtubule dynamics. Furthermore, RHR-S inhibited organismal death, morbidity and mortality, necrosis, and apoptosis.
CONCLUSION: Subnormothermic RHR mitigates IRI and preserves hepatic mitochondrial function after warm and cold hepatic ischemia. This organ resuscitative therapy may also trigger the activation of protective genes against IRI. Subnormothermic RHR has potential applicability to clinical liver transplantation.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 34387201      PMCID: PMC8840998          DOI: 10.1097/SLA.0000000000005156

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  49 in total

Review 1.  ERK1/2 MAP kinases in cell survival and apoptosis.

Authors:  Zhimin Lu; Shuichan Xu
Journal:  IUBMB Life       Date:  2006-11       Impact factor: 3.885

2.  Machine perfusion of the liver: maintenance of mitochondrial function after 48-hour preservation.

Authors:  J S Kim; K Boudjema; A D'Alessandro; J H Southard
Journal:  Transplant Proc       Date:  1997-12       Impact factor: 1.066

3.  Wnt-β-catenin signaling protects against hepatic ischemia and reperfusion injury in mice.

Authors:  Nadja Lehwald; Guo-Zhong Tao; Kyu Yun Jang; Michael Sorkin; Wolfram T Knoefel; Karl G Sylvester
Journal:  Gastroenterology       Date:  2011-05-04       Impact factor: 22.682

4.  Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis.

Authors:  T Sakai; K J Johnson; M Murozono; K Sakai; M A Magnuson; T Wieloch; T Cronberg; A Isshiki; H P Erickson; R Fässler
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

5.  Identity and function of a cardiac mitochondrial small conductance Ca2+-activated K+ channel splice variant.

Authors:  MeiYing Yang; Amadou K S Camara; Mohammed Aldakkak; Wai-Meng Kwok; David F Stowe
Journal:  Biochim Biophys Acta Bioenerg       Date:  2017-03-22       Impact factor: 3.991

6.  Metabolic changes in the liver graft monitored continuously with microdialysis during liver transplantation in a pig model.

Authors:  Grzegorz Nowak; Johan Ungerstedt; Jan Wernerman; Urban Ungerstedt; Bo-Göran Ericzon
Journal:  Liver Transpl       Date:  2002-05       Impact factor: 5.799

7.  HIF-1α Promotes A Hypoxia-Independent Cell Migration.

Authors:  Liyuan Li; Chikezie O Madu; Andrew Lu; Yi Lu
Journal:  Open Biol J       Date:  2010-01-01

8.  Regulated hepatic reperfusion mitigates ischemia-reperfusion injury and improves survival after prolonged liver warm ischemia: a pilot study on a novel concept of organ resuscitation in a large animal model.

Authors:  Johnny C Hong; Dimitri Koroleff; Victor Xia; Chun Ming Chang; Sergio M Duarte; Junming Xu; Charles Lassman; Jerzy Kupiec-Weglinski; Ana J Coito; Ronald W Busuttil
Journal:  J Am Coll Surg       Date:  2012-02-07       Impact factor: 6.113

9.  Ischemia time impacts recurrence of hepatocellular carcinoma after liver transplantation.

Authors:  Shunji Nagai; Atsushi Yoshida; Marcelo Facciuto; Dilip Moonka; Marwan S Abouljoud; Myron E Schwartz; Sander S Florman
Journal:  Hepatology       Date:  2015-01-30       Impact factor: 17.425

10.  Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation.

Authors:  Ji Hoon Kim; Bo Hwa Sohn; Hyun-Sung Lee; Sang-Bae Kim; Jeong Eun Yoo; Yun-Yong Park; Woojin Jeong; Sung Sook Lee; Eun Sung Park; Ahmed Kaseb; Baek Hui Kim; Wan Bae Kim; Jong Eun Yeon; Kwan Soo Byun; In-Sun Chu; Sung Soo Kim; Xin Wei Wang; Snorri S Thorgeirsson; John M Luk; Koo Jeong Kang; Jeonghoon Heo; Young Nyun Park; Ju-Seog Lee
Journal:  PLoS Med       Date:  2014-12-23       Impact factor: 11.069

View more
  1 in total

1.  Oxygenated versus non-oxygenated flush out and storage of donor livers: An experimental study.

Authors:  Isabel M A Brüggenwirth; Willemijn S van der Plas; Otto B van Leeuwen; Adam M Thorne; Michel Rayar; Vincent E de Meijer; Robert J Porte
Journal:  Artif Organs       Date:  2021-12-16       Impact factor: 2.663

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.